TY - JOUR
T1 - Influenza Vaccine Effectiveness Against Illness and Asymptomatic Infection in 2022–2023
T2 - A Prospective Cohort Study
AU - White, Elizabeth B.
AU - Grant, Lauren
AU - Mak, Josephine
AU - Olsho, Lauren
AU - Edwards, Laura J.
AU - Naleway, Allison
AU - Burgess, Jefferey L.
AU - Ellingson, Katherine D.
AU - Tyner, Harmony
AU - Gaglani, Manjusha
AU - Lutrick, Karen
AU - Caban-Martinez, Alberto
AU - Newes-Adeyi, Gabriella
AU - Duque, Jazmin
AU - Yoon, Sarang K.
AU - Phillips, Andrew L.
AU - Thompson, Mark
AU - Britton, Amadea
AU - Flannery, Brendan
AU - Fowlkes, Ashley
N1 - Publisher Copyright:
© 2024 Published by Oxford University Press on behalf of Infectious Diseases Society of America.
PY - 2025/4/15
Y1 - 2025/4/15
N2 - Background. Previous estimates of vaccine effectiveness (VE) against asymptomatic influenza virus infection based on seroconversion have varied widely and may be biased. We estimated 2022–2023 influenza VE against illness and asymptomatic infection in a prospective cohort. Methods. In the HEROES-RECOVER cohort, adults at increased occupational risk of influenza exposure across 7 US sites provided weekly symptom reports and nasal swabs for reverse transcription–polymerase chain reaction (RT-PCR) influenza testing. Laboratory-confirmed influenza virus infections were classified as symptomatic (≥1 symptom) or asymptomatic during the week of testing. Participants reported demographic information and vaccination through surveys; most sites verified vaccination through medical record and immunization registry review. Person-time was calculated as days from the site-specific influenza season start (September–October 2022) through date of infection, study withdrawal, or season end (May 2023). We compared influenza incidence among vaccinated versus unvaccinated participants overall, by symptom status, and by influenza A subtype, using Cox proportional hazards regression adjusted for site and occupation. We estimated VE as (1 − adjusted hazard ratio) × 100%. Results. In total, 269 of 3785 (7.1%) participants had laboratory-confirmed influenza, including 263 (98%) influenza A virus infections and 201 (75%) symptomatic illnesses. Incidence of laboratory-confirmed influenza illness among vaccinated versus unvaccinated participants was 23.7 and 33.2 episodes per 100 000 person-days, respectively (VE: 38%; 95% CI: 15%–55%). Incidence of asymptomatic influenza virus infection was 8.0 versus 11.6 per 100 000 (VE: 13%; 95% CI: −47%, 49%). Conclusions. Vaccination reduced incidence of symptomatic but not asymptomatic influenza virus infection, suggesting that influenza vaccination attenuates progression from infection to illness.
AB - Background. Previous estimates of vaccine effectiveness (VE) against asymptomatic influenza virus infection based on seroconversion have varied widely and may be biased. We estimated 2022–2023 influenza VE against illness and asymptomatic infection in a prospective cohort. Methods. In the HEROES-RECOVER cohort, adults at increased occupational risk of influenza exposure across 7 US sites provided weekly symptom reports and nasal swabs for reverse transcription–polymerase chain reaction (RT-PCR) influenza testing. Laboratory-confirmed influenza virus infections were classified as symptomatic (≥1 symptom) or asymptomatic during the week of testing. Participants reported demographic information and vaccination through surveys; most sites verified vaccination through medical record and immunization registry review. Person-time was calculated as days from the site-specific influenza season start (September–October 2022) through date of infection, study withdrawal, or season end (May 2023). We compared influenza incidence among vaccinated versus unvaccinated participants overall, by symptom status, and by influenza A subtype, using Cox proportional hazards regression adjusted for site and occupation. We estimated VE as (1 − adjusted hazard ratio) × 100%. Results. In total, 269 of 3785 (7.1%) participants had laboratory-confirmed influenza, including 263 (98%) influenza A virus infections and 201 (75%) symptomatic illnesses. Incidence of laboratory-confirmed influenza illness among vaccinated versus unvaccinated participants was 23.7 and 33.2 episodes per 100 000 person-days, respectively (VE: 38%; 95% CI: 15%–55%). Incidence of asymptomatic influenza virus infection was 8.0 versus 11.6 per 100 000 (VE: 13%; 95% CI: −47%, 49%). Conclusions. Vaccination reduced incidence of symptomatic but not asymptomatic influenza virus infection, suggesting that influenza vaccination attenuates progression from infection to illness.
KW - asymptomatic infection
KW - cohort
KW - influenza
KW - symptomatic illness
KW - vaccines
UR - https://www.scopus.com/pages/publications/105003944644
UR - https://www.scopus.com/inward/citedby.url?scp=105003944644&partnerID=8YFLogxK
U2 - 10.1093/cid/ciae491
DO - 10.1093/cid/ciae491
M3 - Article
C2 - 39446477
AN - SCOPUS:105003944644
SN - 1058-4838
VL - 80
SP - 893
EP - 900
JO - Clinical Infectious Diseases
JF - Clinical Infectious Diseases
IS - 4
ER -